Ľubomíra Fábryová
High risk of cardio-cerebrovascular diseases in type 2 diabetic patients is linked with concomitant occurrence of other risk factors for atherosclerosis. At present a large number of diabetics are treated with new group of antidiabetic agents – incretins. In addition to its effect on glycaemic control (fasting and postprandial glycaemia, glycated haemoglobin, and glycaemic variability) there is a growing number of evidence about their ability to improve postprandial lipid abnormalities in this high-risk population. The exact mechanism of control of postprandial dyslipidaemia through the effect of GLP-1 remains still unclear. We can determine three levels of modulation of postprandial lipid metabolism ‒ strengthening of GLP - 1R signalling in the liver, pancreas and intestine. Currently available data support a possible class effect, but also point to differences between the DPP - 4 inhibitors in the modulation of fasting and postprandial lipid and lipoprotein metabolism. In view of the latest results of long-term clinical trials with gliptins we will have to wait for profiling of a long-term safety profile in high-risk populations of type 2 diabetic patients.